Atomoxetine and Neuropsychological Function in Children With Attention-Deficit/Hyperactivity Disorder: Results of a Pilot Study
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
This pilot longitudinal study using measures from parents and teachers evaluated the effects of flexible doses of atomoxetine (ATX) on neuropsychological and functional outcomes in 21 children with attention-deficit/hyperactivity disorder (ADHD) (mean age, 8.0 +/- 1.3 years; inattentive subtype, 71.4%; combined subtype, 28.6%). Among 16 children completing 6 months of ATX treatment, neuropsychological function measured by the NEPSY instrument found significant improvement from baseline in the memory and learning domain (p = 0.01); this change was also seen in an age- and sex-matched healthy control group (p = 0.011). The patient group showed significant improvement on the Test of Everyday Attention (TEA-Ch) and parent and teacher versions of the Behavior Rating Inventory of Executive Function (BRIEF), which assess attentional and executive processes, respectively. Functional improvement was also observed on the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) and parent and teacher versions of the ADHD Rating Scale (ADHDRS-IV), and the investigator-rated Clinical Global Impressions-Severity (CGI-S) scale evidenced reductions in ADHD symptoms. These findings suggest that potential benefits of ATX treatment may extend beyond reduction of core ADHD symptoms to amelioration of some neuropsychological and functional deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willcutt, E. G., Doyle, A. E., Nigg, J. T., Faraone, S. V., & Pennington, B. F. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.006 · Cited by 3,568
TEST REVIEW behavior rating inventory of executive function.
Gioia, G. A., Isquith, P. K., Guy, S. C., & Kenworthy, L. (2000) · Child Neuropsychology · doi:10.1076/chin.6.3.235.3152 · Cited by 1,925 · cited 1×
“…in comparison with similar behavioral rating systems, and reported reliability coefficients for internal consistency range from 0.80 to 0.98, with a test–retest reliability for a parent rating subsample of 0.76–0.85, and that for a teacher rating subsample of 0.83–0.92 (Gioia et al. 2000).”
ResultInfluentialBIEDERMAN, J., MONUTEAUX, M. C., MICK, E., SPENCER, T., WILENS, T. E., SILVA, J. M., SNYDER, L. E., & FARAONE, S. V. (2006) · Psychological Medicine · doi:10.1017/s0033291705006410 · Cited by 850
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Manly, T., Anderson, V., Nimmo‐Smith, I., Turner, A., Watson, P., & Robertson, I. H. (2001) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00806 · Cited by 693
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
NIGG, J. T., & CASEY, B. J. (2005) · Development and Psychopathology · doi:10.1017/s0954579405050376 · Cited by 593
Klassen, A. F., Miller, A., & Fine, S. (2004) · Pediatrics · doi:10.1542/peds.2004-0844 · Cited by 565 · cited 3×
“The effectiveness of medications for ADHD has historically been assessed using changes in core behavioral symptom checklists and rating scales (Klassen et al. 2004).”
Profiles of everyday executive function in acquired and developmental disorders.
Gioia, G. A., Isquith, P. K., Kenworthy, L., & Barton, R. M. (2002) · Child Neuropsychology · doi:10.1076/chin.8.2.121.8727 · Cited by 498 · cited 2×
“This rating scale consists of 86 items and provides a global composite score of executive function and subscale scores for behavioral regulation and meta-cognition (Gioia et al. 2002).”
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 3×
“Clinical trials show that ATX is effective and well tolerated in reducing ADHD symptoms in children, adolescents, and adults (Michelson et al. 2001; Spencer et al. 2002; Michelson et al. 2003; Kelsey et al. 2004; Weiss et al. 2005; Kratochvil et al. 2007).”
Influential
Cited by
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“Teacher rating of ADHD 19 [19, 20, 63, 98, 102–104, 109, 115, 119, 138, 149, 151, 155, 163, 165–168]”
BackgroundInfluentialBari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105
“Finally, the SNARI atomoxetine improves attention in ADHD patients (Barry et al. 2009; Chamberlain et al. 2007; Maziade et al. 2009), healthy volunteers (Chamberlain et al.”
BackgroundWu, E. Q., Hodgkins, P., Ben-Hamadi, R., Setyawan, J., Xie, J., Sikirica, V., Du, E. X., Yan, S. Y., & Erder, M. H. (2012) · CNS Drugs · doi:10.2165/11633900-000000000-00000 · Cited by 58
“In addition, studies have shown that stimulants and non-stimulants could improve neuropsychological, functional and behavioural outcomes and school performance during long-term treatments.([7,17,40])”
BackgroundBanaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0193-z · Cited by 41
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Metadata
- Authors
- Maziade, M., Rouleau, N., Lee, B., Rogers, A., Davis, L., & Dickson, R.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-12
- Volume
- 19
- Issue
- 6
- Pages
- 709-718
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2085942575
- Cited by
- 57
- References
- 18
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.